The Role of IDH Inhibitors in Hematologic Malignancies

AML What Is It and How Did It Get There?

Key Points From De Novo AML Genome Atlas-1

AML A Long List of Prognostic Features

Selected Targeted Therapy in AML

The Evolution of the Discovery of IDH Mutations in Cancer by Year

IDH Mutations Also Found in MDS, NHL and Range of Solid Tumors

IDH Mutations as a Target in AML

AG-221 Preclinical Data

Phase 1 Study of AG-120 in IDH1-Mutant Hematologic Malignancies

Phase 1 Study of AG-221 in IDH2-Mutant Hematologic Malignancies

Results of AG-221 Phase 1 Study

Responses With AG-221

Differentiation Effect in the Bone Marrow

IDH1 (AG-120) and IDH2 (AG-221) Inhibitors: Ongoing and Planned Studies

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)